benserazide

E804591

Benserazide is a peripheral dopa decarboxylase inhibitor used in combination with levodopa to enhance its effectiveness and reduce side effects in the treatment of Parkinson’s disease.

All labels observed (1)

Label Occurrences
benserazide canonical 2

How this entity was disambiguated

Statements (49)

Predicate Object
instanceOf antiparkinsonian agent ⓘ
aromatic L-amino acid decarboxylase inhibitor ⓘ
peripheral dopa decarboxylase inhibitor ⓘ
pharmaceutical drug ⓘ
actsOnEnzyme dopa decarboxylase ⓘ
commonAdverseEffect diarrhea ⓘ
dyskinesia when combined with levodopa ⓘ
nausea ⓘ
orthostatic hypotension ⓘ
vomiting ⓘ
contraindication concomitant use with non-selective MAO inhibitors ⓘ
narrow-angle glaucoma ⓘ
severe hepatic impairment ⓘ
severe renal impairment ⓘ
crossesBloodBrainBarrier no ⓘ
developedFor enhancing levodopa therapy in Parkinson’s disease ⓘ
eliminationRoute renal ⓘ
hasATCCode N04BA02 ⓘ
hasBioavailability low ⓘ
hasCASNumber 322-35-0 ⓘ
hasChEMBLID CHEMBL1082 ⓘ
hasChemicalFormula C10H15N3O5 ⓘ
hasDrugBankID DB01232 ⓘ
hasHalfLife approximately 1.5 hours ⓘ
hasIUPACName (2S)-2-amino-3-hydroxy-N'-[(2S,3R)-2,3,4-trihydroxy-3-(hydroxymethyl)butyl]propanediamide ⓘ
hasMolarMass 257.246 g/mol ⓘ
hasPregnancyCategory C (varies by jurisdiction) ⓘ
hasProteinBinding low ⓘ
hasPubChemCID 2327 ⓘ
hasRouteOfAdministration oral ⓘ
hasUNII P8G79501I4 ⓘ
isComponentOf Madopar ⓘ
linked to: carbidopa

Prolopa ⓘ
co-beneldopa ⓘ
legalStatusInAustralia prescription only ⓘ
legalStatusInCanada prescription only ⓘ
legalStatusInEuropeanUnion prescription only ⓘ
legalStatusInUnitedStates not approved ⓘ
mechanismOfAction inhibits peripheral aromatic L-amino acid decarboxylase ⓘ
metabolism hepatic ⓘ
primaryEffect increases availability of levodopa to the brain ⓘ
reduces peripheral conversion of levodopa to dopamine ⓘ
reducesAdverseEffect cardiovascular side effects of levodopa ⓘ
nausea ⓘ
vomiting ⓘ
reducesSideEffectsOf levodopa ⓘ
therapeuticUse treatment of Parkinson’s disease ⓘ
treatment of parkinsonism ⓘ
usedInCombinationWith levodopa ⓘ

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.